GH

Chris Freeman

Known title: Chief Commercial OfficerCIK: 0001871615

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target. Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.

this person other insiders at GH

Transaction History

GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$549K
GH▲ Buy$3.9M
GH▲ Buy$800K
GH▼ Sell$580K
GH▼ Sell$1.2M
GH▼ Sell$6.0M
GH▼ Sell$3.0M
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$536K
GH▲ Buy$0
GH▼ Sell$77K
GH▼ Sell$2.9M
GH▲ Buy$802K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$433K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$609K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$1.0M
GH▲ Buy$0
GH▼ Sell$61K
GH▼ Sell$38K
GH▼ Sell$25K
GH▼ Sell$24K
GH▼ Sell$1.2M
GH▼ Sell$353K
GH▼ Sell$682K
GH▼ Sell$42K
GH▼ Sell$316K
GH▼ Sell$48K
GH▼ Sell$76K
GH▼ Sell$414K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$360K
GH▼ Sell$33K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$78K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$132K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$47K
GH▲ Buy$0
GH▼ Sell$17K
GH▼ Sell$67K
GH▲ Buy$0
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$36K
GH▲ Buy$0
GH▼ Sell$21K
GH▲ Buy$0
GH▼ Sell$80K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$16K
GH▲ Buy$0
GH▼ Sell$21K
GH▲ Buy$0
GH▲ Buy$0
GH▼ Sell$87K
GH▲ Buy$0
GH▼ Sell$11K
GH▲ Buy$0
GH▼ Sell$17K
GH▲ Buy$0
GH▼ Sell$63K
GH▲ Buy$0
GH▼ Sell$51K
GH▲ Buy$0
GH▼ Sell$65K

We use analytics to understand how market-wall is used. No personal data is sold.